1060804-53-6|2-Chloro-5-hydroxyisonicotinaldehyde| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 1060804-53-6 ] Purity: 98% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 1060804-53-6 ]

CAS No. :	1060804-53-6
Formula :	C₆H₄ClNO₂
M.W :	157.55
SMILES Code :	O=CC1=C(O)C=NC(Cl)=C1
MDL No. :	MFCD13189121
InChI Key :	HZSDMQCOOUNXRC-UHFFFAOYSA-N
Pubchem ID :	56956219

Safety of [ 1060804-53-6 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

Computational Chemistry of [ 1060804-53-6 ] Show Less

Physicochemical Properties

Num. heavy atoms	10
Num. arom. heavy atoms	6
Fraction Csp3	0.0
Num. rotatable bonds	1
Num. H-bond acceptors	3.0
Num. H-bond donors	1.0
Molar Refractivity	36.66
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	50.19 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	0.9
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	1.47
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.25
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	-0.22
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.67
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.01

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-2.12
Solubility	1.19 mg/ml ; 0.00757 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-2.13
Solubility	1.17 mg/ml ; 0.0074 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.0
Solubility	1.57 mg/ml ; 0.00998 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.22 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	2.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.51

Application In Synthesis of [ 1060804-53-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 1060804-53-6 ]

[ 1060804-53-6 ] Synthesis Path-Downstream 1~22

1
[ 1060804-53-6 ]
[ 407-25-0 ]
[ 1228267-89-7 ]

Yield	Reaction Conditions	Operation in experiment
90%	With triethylamine; In dichloromethane; at 20℃;	100 mL of CH2Cl2 was put into the compound 2-chloro-5-hydroxy-pyridine-4-carbaldehyde (13.7 g, 87 mmol) and agitated, and triethylamine (13.3 g, 130.5 mmol), and trifluoroacetic anhydride (25.8 g, 130.5 mmol) were slowly dropped thereto. The mixture was agitated at normal temperature for 2 hours, water and CH2Cl2 were added to separate the organic layer, and the organic extract was dried over magnesium sulfate and concentrated under the vacuum. It was purified with CH2Cl2/EtOH to prepare the compound C-26 (22.7 g, yield 90%). MS [M+H]+=289

References: [1]Patent: EP2311826,2011,A2 .Location in patent: Page/Page column 117.

2
[ 1060804-53-6 ]
[ 1445968-07-9 ]

Yield	Reaction Conditions	Operation in experiment
		To a solution of aldehyde 21 a (4.4 g, 27.9 mmol, Anichem) in isopropyl alcohol (180 mL) is added hydroxylamine hydrochloride (5.8 g, 83.8 mmol). The solution is heated to reflux for 1 h, then cooled to RT and the solvent is removed in vacuo. The residue is diluted with EtOAc, washed with sodium bicarbonate solution and dried (Na2S04) to obtain the corresponding oxime. Cyanuric chloride (9.1 g, 49.3 mmol) is added portionwise to DMF (40 mL) at 0C while maintaining the temperature below 25C until cyanuric chloride completely consumed (~1 h). The obtained oxime is added to the solution of DMF at the same temperature and stirred for 1 h. The reaction mixture is quenched by adding water, extracted with EtOAc and washed with NaHC03 solution and brine. The organic layer is dried (Na2S04) and concentrated to give cyanide 21 b.

References: [1]Patent: WO2013/91096,2013,A1 .Location in patent: Page/Page column 43.

3
[ 1060804-53-6 ]
[ 1445968-08-0 ]

References: [1]Patent: WO2013/91096,2013,A1 .

4
[ 1060804-53-6 ]
[ 1445968-10-4 ]

References: [1]Patent: WO2013/91096,2013,A1 .

5
[ 1060804-53-6 ]
[ 1445968-11-5 ]

References: [1]Patent: WO2013/91096,2013,A1 .

6
[ 1060804-53-6 ]
[ 1445968-12-6 ]

References: [1]Patent: WO2013/91096,2013,A1 .

7
[ 41288-96-4 ]
[ 1060804-53-6 ]

References: [1]Patent: WO2013/127268,2013,A1 .
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 8345 - 8368.

8
[ 877133-56-7 ]
[ 1060804-53-6 ]

References: [1]Patent: WO2013/127268,2013,A1 .
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 8345 - 8368.
[3]Patent: WO2019/80878,2019,A1 .

9
[ 1282516-32-8 ]
[ 1060804-53-6 ]

Yield	Reaction Conditions	Operation in experiment
6 g	With hydrogenchloride; In tetrahydrofuran; water; at 60℃; for 1h;	A solution of 2-chloro- 5-(methoxymethoxy)pyridine-4-carbaldehyde ( 12 g, 59.52 mmol, 1.00 equiv) in tetrahydrofuran (80 mL) and 3M HCl (130 mL) was stirred for 1 h at 60C. The reaction mixture was cooled to rt and the pH value of the solution was adjusted to 7 with 5% aqueous sodium carbonate solution. The organic layer was collected and the aqueous layer was extracted with 400 mL of ethyl acetate. The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated under vacuum. The residue was purified on a silica gel column eluted with ethyl acetate/petroleum ether (1 :3) to give 6 g (64%) of 2-chloro-5-hydroxypyridine-4-carbaldehyde as a light yellow solid. TLC: petroleum ether: ethyl acetate=2:1 , Rf = 0.3.

References: [1]Patent: WO2019/80878,2019,A1 .Location in patent: Page/Page column 86; 88.
[2]Patent: WO2013/127268,2013,A1 .Location in patent: Page/Page column 95; 96.
[3]Journal of Medicinal Chemistry,2016,vol. 59,p. 8345 - 8368.

10
[ 1060804-53-6 ]
[ 1315362-16-3 ]

References: [1]Patent: WO2013/127268,2013,A1 .
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 8345 - 8368.

11
[ 1060804-53-6 ]
[ 1454285-47-2 ]

References: [1]Patent: WO2013/127268,2013,A1 .
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 8345 - 8368.
[3]Patent: WO2017/69980,2017,A1 .

12
[ 1060804-53-6 ]
[ 1454285-48-3 ]

References: [1]Patent: WO2013/127268,2013,A1 .
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 8345 - 8368.

13
[ 1060804-53-6 ]
[ 1454285-49-4 ]

References: [1]Patent: WO2013/127268,2013,A1 .
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 8345 - 8368.

14
[ 1060804-53-6 ]
[ 1454285-13-2 ]

References: [1]Patent: WO2013/127268,2013,A1 .
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 8345 - 8368.

15
[ 1060804-53-6 ]
[ 96-32-2 ]
[ 1454285-46-1 ]

Yield	Reaction Conditions	Operation in experiment
66%	With potassium carbonate; In N,N-dimethyl-formamide; at 50℃; for 2h;	A solution of <strong>[1060804-53-6]2-chloro-5-hydroxypyridine-4-carbaldehyde</strong> (5.7 g, 36. 18 mmol, 1.00 equiv), methyl 2-bromoacetate (7.8 g, 50.99 mmol, 1 .41 equiv) and potassium carbonate (6.5 g) in DMF (100 mL) was stirred for 2 h at 50C The resulting solution was diluted with 400 mL of ethyl acetate and washed with 2x200 mL of FL . The organic layer was dried over anhydrous sodium sulfate and concentrated under vacuum. The residue was purified on a silica gel column eluted with ethyl acetate/petroleum ether ( 1 :3) to yield 5.5 g (66%) of methyl 2-[(6-chloro-4-formylpyridin-3-yl)oxy]acetate as a light yellow solid. TLC: petroleum ethe ethyl acetate=2: 1 , Rf = 0.3.

References: [1]Patent: WO2013/127268,2013,A1 .Location in patent: Page/Page column 95; 96; 97.
[2]Journal of Medicinal Chemistry,2016,vol. 59,p. 8345 - 8368.

16
[ 1060804-53-6 ]
[ 96-32-2 ]
[ 1315362-16-3 ]

Yield	Reaction Conditions	Operation in experiment
79%	With potassium carbonate; In N,N-dimethyl-formamide; at 80℃; for 8h;	j00489j To a mixture of <strong>[1060804-53-6]2-chloro-5-hydroxyisonicotinaldehyde</strong> (4.0 g, 25 mmol) and methyl 2- bromoacetate (5.8 g, 38 mmol) in N,N-dimethylformamide (40 mL) under nitrogen at room temperature was added potassium carbonate (6.9 g, 50 mmol). The reaction mixture was stirred at 80 C for 8 hours, then diluted with water (100 mL) and extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine (2 x 100 mL), dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by silica gel silica gel chromatography [petroleum ether: ethyl acetate = 25:11 to give compound B-109 (4.2 g, 79% yield) as a white solid. LCMS (E): tR=0.68 mm., 212.6 mlz (M+1).

References: [1]Patent: WO2017/69980,2017,A1 .Location in patent: Paragraph 00488; 00489.
[2]Patent: WO2019/80878,2019,A1 .Location in patent: Page/Page column 86; 88.

17
[ 1060804-53-6 ]
5-chlorofuro[2,3-c]pyridine [ No CAS ]

References: [1]Patent: WO2017/69980,2017,A1 .

18
[ 1060804-53-6 ]
methyl 5-(4-(4-ethylpiperazin-1-yl)-2-nitrophenylamino)furo[2,3-c]pyridine-2-carboxylate [ No CAS ]